HomeNews & Events

News & Events

2025.08
13

Interim Results Announcement For The Six Months Ended 30 June 2025

2025.08
13

BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan

- BioDlink’s bevacizumab injection secures marketing authorization in Colombia and Pakistan followingits recent approval in Nigeria, marking key regulatory milestones in high-needemerging markets.- GMP certification in Brazil, Colombia,and Argentina spans
2025.07
04

BioDlink Drives Global Biologics Innovation with Ecosystem Partners

- BioDlink convenes a peer advisory eventbringing together biotech CEOs, MNC leaders and researchers to discussinnovation and collaboration strategies- Integrated one-stop technology platformhelps innovative biotech companies launch life-saving therapies
2025.06
16

BioDlink's Bevacizumab Approved for Market Launch in Nigeria, Accelerating Global Expansion

BioDlinks Bevacizumab Injection has been granted marketing authorization by Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC), following GMP certifications in Brazil (a PIC/S member), Colombia, Egypt, Indonesia, and Argenti……
2025.06
05

BioDlink Strengthens Global Compliance with Argentina GMP Certification

GMP certification from Argentina, marking a key step in its global expansion and regulatory recognition
2025.05
21

BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth

Demonstrated BioDlink’s capability to develop and deliver globally trusted biosimilars,especially antibody drugs, with proven consistency and reliability
2025.05
08

BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate

BioDlink provided end-to-end development and manufacturing support, showcasing its industry-leading ADC capabilities.
2025.03
12

BioDlink Announces 2024 Annual Results